US2002010211A1PendingUtilityA1

Use of alpha-linolenic acid metabolites for treatment or prevention of cancer

46
Priority: Sep 10, 1999Filed: Jul 13, 2001Published: Jan 24, 2002
Est. expirySep 10, 2019(expired)· nominal 20-yr term from priority
Inventors:Mark ObukowiczAyman KabakibiSusan L. GreenLisa M. OlsonJulie Lindemann
A61K 31/557A23L 33/12A61P 35/04A61P 35/00A61K 31/202
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Cancer in a mammal can be treated or prevented by administering to a mammal in need thereof a cancer inhibiting amount of metabolite(s) of α-linolenic acid, such as stearidonic acid (18:4 n-3), eicosatetraenoic acid (20:4 n-3), docosapentaenoic acid (22:5 n-3) and mixtures thereof, especially metabolites including stearidonic acid.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method for treating or preventing cancer in a mammal, said method comprising administering to a mammal in need thereof a cancer inhibiting amount of a metabolite of α-linolenic acid selected from the group consisting of stearidonic acid (18:4 n-3), eicosatetraenoic acid (20:4 n-3), docosapentaenoic acid (22:5 n-3) and mixtures thereof.  
     
     
         2 . A method according to  claim 1 , wherein said cancer is colon cancer, breast cancer, prostate cancer or lung cancer.  
     
     
         3 . A method according to  claim 1 , wherein said metabolite comprises stearidonic acid (18:4 n-3).  
     
     
         4 . A method according to  claim 1 , wherein said metabolite consists essentially of stearidonic acid (18:4 n-3).  
     
     
         5 . A method according to any one of claims  1 - 4 , wherein said metabolite is in the form of a lipid, a carboxylate salt, an ester, a triglyceride, an amide or another pharmacologically acceptable carboxylic acid derivative.  
     
     
         6 . A method according to any one of claims  1 - 4 , wherein said metabolite is in the form of a triglyceride.  
     
     
         7 . A method according to any one of claims  1 - 4 , wherein said metabolite is in the form of an ester.  
     
     
         8 . A method according to any one of claims  1 - 4 , wherein said metabolite is administered in a dosage amount from about 1 mg/Kg/day to about 300 mg/Kg/day.  
     
     
         9 . A method according to any one of  claim 5 , wherein said metabolite is administered in a dosage amount from about 1 mg/Kg/day to about 300 mg/Kg/day.  
     
     
         10 . A method according to any one of  claim 6 , wherein said metabolite is administered in a dosage amount from about 1 mg/Kg/day to about 300 mg/Kg/day.  
     
     
         11 . A method according to  claim 5 , wherein said metabolite is administered in a dosage amount from about 10 mg/Kg/day to about 150 mg/Kg/day.  
     
     
         12 . A method according to  claim 6 , wherein said metabolite is administered in a dosage amount from about 10 mg/Kg/day to about 150 mg/Kg/day.  
     
     
         13 . A method according to  claim 7 , wherein said metabolite is administered in a dosage amount from about 10 mg/Kg/day to about 150 mg/Kg/day.  
     
     
         14 . A method according to  claim 8 , wherein said metabolite is administered in a dosage amount from about 10 mg/Kg/day to about 150 mg/Kg/day.  
     
     
         15 . A method according to any one of claims  1 - 4 , wherein said metabolite is administered in a pharmaceutical preparation, a nutritional preparation or a food preparation.  
     
     
         16 . A method according to  claim 15 , wherein said metabolite is administered in a food preparation.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.